Status:

COMPLETED

A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate

Lead Sponsor:

Eli Lilly and Company

Conditions:

Healthy

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

This study will assess the safety, tolerability and blood concentrations of lasmiditan and topiramate together compared to lasmiditan and topiramate separately. Information about any side effects that...

Eligibility Criteria

Inclusion

  • Are healthy males or females (of non-child bearing potential), as determined by medical history and physical examination
  • Have a body mass index of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive

Exclusion

  • Have known allergies to lasmiditan, topiramate, related compounds or any components of the formulation of lasmiditan or topiramate
  • Have an abnormal supine blood pressure, defined as systolic blood pressure less than (\<) 90 or great (\>) 140 millimeters of mercury (mmHg) or diastolic blood pressure \<60 or \>90 mmHg at screening
  • Have known or ongoing psychiatric disorders considered clinically significant by the investigator or demonstrate suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS)
  • Have a clinically significant abnormality in the neurological examination
  • Have current or a history of orthostatic hypotension (\>20-mmHg drop in systolic blood pressure, or \>10-mmHg drop in diastolic blood pressure) with or without dizziness and/or syncope at screening or admission to the Clinical Research Unit (CRU) upon repeat testing
  • Have an estimated glomerular filtration rate using Modification of Diet in Renal Disease \<60 milliliter per minute (mL/min) per 1.73 meter squared (m²)
  • Have a history of glaucoma
  • Have a history of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

Key Trial Info

Start Date :

October 16 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 2 2017

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03308669

Start Date

October 16 2017

End Date

December 2 2017

Last Update

November 27 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Covance Madison CRU

Madison, Wisconsin, United States, 53704